Novogen to Present at the 2015 Marcum Microcap Conference

May 26, 2015, 07:00 ET from Novogen Ltd

SYDNEY and NEW YORK, May 26, 2015 /PRNewswire/ -- US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ: NVGN), announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City at the Grand Hyatt Hotel.

The Company's presentation by Dr. Graham Kelly, Novogen Chairman and CEO, is scheduled to begin at 9.30 a.m. ET and will be available via a live webcast. To access the webcast, go to http://wsw.com/webcast/marcum3/nvgn.

The annual Marcum MicroCap Conference is a showcase for public companies with less than $500 million in market capitalization. This year's keynote speaker will be Richard S. Fuld, Jr., Chairman of Matrix Advisors and former Chairman of Lehman Brothers.

For more information or to register, please visit the conference website at http://www.marcumllp.com/microcap or download the free official conference app for the iPhone, iPad, or for Android mobile devices in Apple's App Store and the Google Play Market.

About the Marcum MicroCap Conference

The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors and provides investors with the opportunity to meet with management of these companies on a one-on-one basis.  Industry sectors include Technology, Media & Internet; Software & Business Services; Life Science & Healthcare; Retail & Consumer Products; Energy & Natural Resources; and Industrials. The conference additionally includes a full agenda of panel discussions on issues of strategic importance to small cap issuers and investors, moderated by industry leaders.

The Marcum MicroCap Conference attracts fund managers and high net worth investors focusing on small cap equities. Over 2,000 participants from all segments of the microcap market attend each year, including senior management, finance and legal executives, venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, buy- and sell-side analysts, and service providers to the microcap marketplace.

For complete information about the 2015 Marcum MicroCap Conference, visit www.marcumllp.com/microcap.

About Novogen

Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug technology platforms yielding drug candidates that are first-in-class with potential application across a broad range of degenerative diseases. In the oncology field, the ultimate objective is to see both drug technologies used in combination as first-line therapy across most forms of cancer, with the objective of preventing tumor recurrence. This objective is based on a strategy of achieving comprehensive destruction of the full hierarchy of cells within a tumor with the super-benzopyran technology platform killing the tumor-initiating cells and the anti-tropomyosin technology, combined with vinca alkaloids, to deliver a potent chemical debulking effect on their daughter cells.

For more information, please visit www.novogen.com

Corporate Contact

Media Enquiries

Dr. Graham Kelly

Prue Kelly

Executive Chairman & CEO

Media Officer

Novogen Group

Novogen Group

Graham.Kelly@novogen.com  

Prue.Kelly@novogen.com

+61 (0) 2 9472 4101

+61 (0) 2 9472 4101

Forward looking statement

All statements other than statements of historical fact included in this announcement including, without limitation, statements regarding future plans and objectives of Novogen Limited ("Novogen") are forward-looking statements. When used in this announcement, forward-looking statements can be identified by words such as 'may', 'could', 'should', 'would', 'believes', 'estimates', 'targets', 'expects' or 'intends' and other similar words that involve risks and uncertainties.

Such statements relate to future events and expectations and as such involve known and unknown risks and uncertainties. These risks and uncertainties include, among other things, market conditions, weather risks, economic and political risks.

These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this announcement, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Novogen, its directors and management, which could cause Novogen's actual results to differ materially from the results expressed or anticipated in these statements.

Novogen cannot and does not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements. Actual results, actions, and developments may differ materially from those expressed or implied by those forward-looking statements depending on a variety of factors.

Novogen does not undertake to update or revise forward- looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this announcement, except where required by applicable law and stock exchange listing requirements.

SOURCE Novogen Ltd



RELATED LINKS

http://www.novogen.com


http://www.marcumllp.com/microcap